Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

Biochemical Pharmacology

Volumn 55, Issue 11, 1998, Pages 1827-1834

  Bauer, Kenneth S ^a   Dixon, Shannon C ^a   Figg, William D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Angiogenesis; Aorta; Metabolism; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; DRUG METABOLITE; THALIDOMIDE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; DRUG METABOLISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AORTA, THORACIC; CELL DIVISION; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; HUMANS; MICROSOMES, LIVER; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RABBITS; RATS; SPECIES SPECIFICITY; THALIDOMIDE; TUMOR CELLS, CULTURED;

EID: 0032100604     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00046-X     Document Type: Article

References (27)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 181:1971;182-186.
2. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 324:1991;1-8.
3. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143:1993;401-409.
4. Heimann R., Ferguson D., Powers C., Recant W.M., Weichselbaum R.R., Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst. 88:1996;1764-1769.
5. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:1994;4082-4085.
6. Vesela D., Vesely D., Jelinek R. Embryotoxicity in chick embryo of thalidomide hydrolysis products following metabolic activation by rat liver homogenate. Funct Dev Morphol. 4:1994;313-316.
7. Pollard M. Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. Cancer Lett. 101:1996;21-24.
8. Gutman M., Szold A., Ravid A., Lazzauskas T., Merimsky O., Klausner J.M. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. 16:1996;3673-3678.
9. Hatfill S.J., Fester E.D., DeBeer D.P., Bohm L. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. Leukemia Res. 15:1991;129-136.
10. Gibson G.G., Skett P. Introduction to Drug Metabolism. 2nd Edn. 1994;Chapman & Hall, New York.
11. Ryan D.E., Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther. 45:1990;153-239.
12. Evans R.R., Relling M.V. Automated high-performance liquid chromatographic assay for the determination of 7-ethoxycoumarin and umbelliferone. J Chromatogr. 578:1992;141-145.
13. Nicosia R.F., Ottinetti O. Growth of microvessels in serum-free matrix culture of rat aorta: A quantitative assay of angiogenesis in vitro. Lab Invest. 63:1990;115-122.
14. Carlini R.G., Reyes A.A., Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 47:1995;740-745.
15. Pinkus G.S., Etheridge C.L., O'Connor E.M. Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffin-embedded neoplasms using monoclonal and polyclonal antibodies. Am J Clin Pathol. 85:1986;269-277.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
17. Hanahan D., Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
18. Schmahl H.J., Nau H., Neubert D. The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma phamacokinetics in the marmoset monkey. Arch Toxicol. 62:1988;200-204.
19. Winckler K., Klinkmüller K.D., Schmahl H.J. Determination of the thalidomide analogues 2-(2,6-dioxopiperidine-3-yl)phthalimidine (EM 12), 2-(2,6-dioxopiperidine-4-yl)phthalimidine (EM 16) and their metabolites in biological samples. J Chromatogr. 488:1989;417-425.
20. Czejka M.J., Koch H.P. Determination of thalidomide and its major metabolites by high-performance liquid chromatography. J Chromatogr. 413:1987;181-187.
21. Fabro S., Schumacher H., Smith R.L., Stagg R.B.L., Williams R.T. The metabolism of thalidomide: Some biological effects of thalidomide and its metabolites. Br J Pharmacol. 25:1965;352-362.
22. Günzler V., Hanauske-Abel H.M., Tschank G., Schulte-Wissermann H. Immunological effects of thalidomide: Inactivity of the drug and several of its hydrolysis products in mononucleocyte proliferation tests. Arzneimittelforschung. 36:1986;1138-1141.
23. Jönsson N.A. Chemical structure and teratogenic properties: III. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues. Acta Pharm Suec. 9:1972;521-542.
24. Chen T.L., Vogelsang G.B., Petty B.G., Brundrett R.B., Noe D.A., Santos G.W., Colvin O.M. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos. 17:1989;402-405.
25. Simmons B.R., Lush R.M., Figg W.D. A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. Anal Chim Acta. 339:1997;91-97.
26. Vogelsang G.B., Farmer E.R., Hess A.D., Altamonte V., Beschorner W.E., Jabs D.A., Corio R.L., Levin L.S., Colvin O.M., Wingard J.R., Santos G.W. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 326:1992;1055-1058.
27. Gordon G.B., Spielberg S.P., Blake D.A., Balasubramanian V. Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA. 78:1981;2545-2548.